ATE152352T1 - Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion - Google Patents

Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion

Info

Publication number
ATE152352T1
ATE152352T1 AT90122096T AT90122096T ATE152352T1 AT E152352 T1 ATE152352 T1 AT E152352T1 AT 90122096 T AT90122096 T AT 90122096T AT 90122096 T AT90122096 T AT 90122096T AT E152352 T1 ATE152352 T1 AT E152352T1
Authority
AT
Austria
Prior art keywords
chem
hydrogen
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
AT90122096T
Other languages
English (en)
Inventor
Jun Inoue
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE152352T1 publication Critical patent/ATE152352T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
AT90122096T 1989-11-20 1990-11-19 Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion ATE152352T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1301413A JPH03161441A (ja) 1989-11-20 1989-11-20 メイラード反応阻害剤

Publications (1)

Publication Number Publication Date
ATE152352T1 true ATE152352T1 (de) 1997-05-15

Family

ID=17896581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90122096T ATE152352T1 (de) 1989-11-20 1990-11-19 Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion

Country Status (7)

Country Link
EP (1) EP0433679B1 (de)
JP (1) JPH03161441A (de)
KR (1) KR910009665A (de)
AT (1) ATE152352T1 (de)
CA (1) CA2029421A1 (de)
DE (1) DE69030616T2 (de)
ES (1) ES2100861T3 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP3988838B2 (ja) * 1996-05-29 2007-10-10 日本製粉株式会社 化粧料
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CA2664159C (en) 1998-08-24 2013-06-04 Toshio Miyata Carbonyl-stress improving agent and peritoneal dialysate
FR2797443B1 (fr) * 1999-08-13 2003-10-31 Lafon Labor Procede de prepartion de quinoleine-5,8-diones
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
FR2864535B1 (fr) * 2003-12-24 2006-12-22 Merck Sante Sas Derives acides de quinoline et leurs applications en therapeutique
JP4739705B2 (ja) * 2004-07-21 2011-08-03 ロート製薬株式会社 内服用組成物
JP4971403B2 (ja) * 2009-09-25 2012-07-11 パナソニック株式会社 除毛機
JP4894902B2 (ja) * 2009-09-25 2012-03-14 パナソニック電工株式会社 除毛機
CN108558906A (zh) * 2018-05-21 2018-09-21 日照市普达医药科技有限公司 一种治疗白内障药物苯并吩噁嗪类化合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359455A (en) * 1979-10-30 1982-11-16 Sunstar Hamigaki Kabushiki Kaisha Diagnostic test composition for dental caries activity
IN164557B (de) * 1986-08-27 1989-04-08 Hoechst Ag
JPH01211595A (ja) * 1988-02-18 1989-08-24 Kikkoman Corp 新規N−アセチル−β−D−グルコサミン誘導体、その製法及びN−アセチル−β−D−グルコサミニダーゼ活性測定用試薬への利用
US5112739A (en) * 1988-08-02 1992-05-12 Polaroid Corporation Enzyme controlled release system

Also Published As

Publication number Publication date
DE69030616T2 (de) 1997-12-11
CA2029421A1 (en) 1991-05-21
DE69030616D1 (de) 1997-06-05
EP0433679A3 (en) 1992-03-04
EP0433679B1 (de) 1997-05-02
KR910009665A (ko) 1991-06-28
EP0433679A2 (de) 1991-06-26
JPH03161441A (ja) 1991-07-11
ES2100861T3 (es) 1997-07-01

Similar Documents

Publication Publication Date Title
ATE152352T1 (de) Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion
DK0430045T3 (da) Ascorbinsyretocopherylphosphatdiestere til hæmning af Maillards reaktion
IE861820L (en) 2-hydroxy-2-phenylethylaminotetralines
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
IE890500L (en) 3-alkenyl-1-azabicyclo£3.2.0|hept-2-ene-2-carboxylic acid compounds
GR3018387T3 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them.
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
ATE157980T1 (de) Tetrahydropyrrolo(1,2-a>pyrazin-4-spiro-3'- pyrrolidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
UA42733C2 (uk) Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить
ATE71092T1 (de) Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.
AU3595689A (en) Anthracycline derivatives having cytostatic activity
GB8608893D0 (en) D-nor-7-ergoline derivatives
EP0541726A4 (en) Growth factor compositions, preparation and use
AU2013888A (en) Uricosuric composition
TW353071B (en) Chromene compounds with neutroleptic activity, their preparation and pharmaceutical compositions
ATE97902T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.
TW360630B (en) A secoaporphine compounds on arrhythmia
TH13247EX (th) อนุพันธ์เททราไฮโดรฟิร์โรโล [1,2-a]ไพราชีน-4-สไพโร-3'-พิริโรลิดีน กรรมวิธีสำหรับเตรียมสารนั้นและสารผสมในทางเภสัชกรรมซึ่งมีสารนั้น

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties